Tscan Therapeutics is trading at $0.90 (up 6.3%) in pre-market action, rebounding from yesterday’s 5.1% decline to $0.85.
- The move appears to be a modest recovery following broad weakness across the biotech and growth sectors rather than a reaction to new company-specific news.
- There are currently no fresh headlines, earnings reports, FDA decisions, or analyst calls tied to the stock to account for the price volatility.